SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Director/PDMR Shareholding

8 Mar 2017 07:00

RNS Number : 8101Y
Collagen Solutions PLC
08 March 2017
 

 

Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")

 

8 March 2017

Grant of Options

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that options over 500,000 ordinary shares of 1p each in the Company ("Ordinary Shares") were granted on 7 March 2017 to Bradley Selman, VP Global Sales & Marketing ("Options").

 

The Options have an exercise period of ten years from grant and have an exercise price per Option of 5.75p. The Options vest in full upon the closing middle market price per Ordinary Share exceeding 27p or EPS for the relevant financial year achieving 1p during the exercise period.

 

- Ends -

 

Enquiries:

 

Collagen Solutions Plc

Contact via Walbrook

Jamal Rushdy, Chief Executive Officer

Gill Black, Chief Financial Officer

Cenkos Securities plc (Nominated Adviser and Broker)

Stephen Keys

Steve Cox

Callum Davidson

Tel: 0207 397 8900

 

 

Walbrook PR

Tel: 020 7933 8780 or collagen@walbrookpr.com

Mike Wort

Mob: 07900 608 002

Anna Dunphy

Mob: 07876 741 001

 

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Bradley Selman

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (VP - Global Sales & Marketing - Executive Team Member)

b)

 

Initial notification /Amendment

 

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Collagen Solutions Plc

 

b)

 

LEI

 

 

N/A

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

 

Option to acquire 1p ordinary shares in Collagen Solutions Plc

 

N/A

 

b)

 

Nature of the transaction

 

 

Grant of Options

c)

 

Price(s) and volume(s)

 

 

Price (exercise): 5.75p

Volume(s): 500,000

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

N/A

 

N/A

 

e)

 

Date of the transaction

 

 

7 March 2017

f)

 

Place of the transaction

 

 

Outside a trading venue

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKFDNPBKKCNK
Date   Source Headline
12th Sep 20167:00 amRNSIssue of Equity
24th Aug 201611:26 amRNSResult of AGM
25th Jul 201611:48 amRNSPosting of Annual Report
19th Jul 20167:15 amRNSHardman research: Focused scalable growth
15th Jul 20167:00 amRNSGrant of Options
12th Jul 20165:12 pmRNSDirector/PDMR Shareholding
12th Jul 201611:51 amRNSHolding(s) in Company
11th Jul 20164:15 pmRNSDirector/PDMR Shareholding
11th Jul 20163:16 pmRNSDirector/PDMR Shareholding
11th Jul 20167:00 amRNSFinal Results
13th Jun 20167:00 amRNSNotice of Results Investor Presentation
4th May 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSLeadership changes and preliminary FY revenue
27th Apr 20165:34 pmRNSHolding(s) in Company
26th Apr 20168:28 amRNSJoint Venture Agreement in China
19th Apr 20167:00 amRNSSupply of collagen materials to Merck
30th Mar 20169:37 amRNSHolding(s) in Company
23rd Mar 20167:00 amRNSResearch collaboration
26th Feb 20161:02 pmRNSHolding(s) in Company
12th Feb 20167:00 amRNSDeath of adviser
3rd Feb 20167:00 amRNSCollagen Solutions present at The Scotsman
22nd Jan 20165:47 pmRNSHolding(s) in Company
21st Jan 201610:14 amRNSChairman's Share Purchase
20th Jan 20167:00 amRNSTrading Update
14th Jan 20165:29 pmRNSHolding(s) in Company
9th Dec 201511:17 amRNSHolding(s) in Company
9th Dec 20157:00 amRNSHardman Issues Research Report
7th Dec 20157:00 amRNSCollagen Solutions Supply Agreement with BBI
2nd Dec 20153:48 pmRNSDirector/PDMR Shareholding
1st Dec 20157:00 amRNSHalf Yearly Report
20th Nov 20153:20 pmRNSDeath of a Director
18th Nov 20157:00 amRNSAppointment of Chief Business Officer
3rd Nov 20157:00 amRNSNotice of Results
28th Sep 20157:00 amRNSCollagen supply agreement to Yucel Medical
22nd Sep 20157:00 amRNSMedical Research Studentship
16th Sep 20157:00 amRNSSupply Agreement with Histogenics Corporation
14th Sep 20157:00 amRNSAcquisition of a regenerative medicine product
3rd Sep 20157:00 amRNSFDA approval for NovaBone product
28th Aug 201510:11 amRNSAGM Statement
28th Aug 20157:00 amRNSJoins consortium developing new treatments
22nd Jul 20157:00 amRNSPosting of Annual Report & Notice of AGM
15th Jul 201510:09 amRNSHardman & Co issues research on Collagen Solutions
14th Jul 20157:00 amRNSPartnership with UCL and Oxford MEStar Ltd
13th Jul 20157:00 amRNSFinal Results
3rd Jul 20152:11 pmRNSNotice of Results
26th Jun 20157:00 amRNSChange of Adviser
22nd Jun 20157:00 amRNSInnovate UK Grant Award
28th May 20157:00 amRNSNew Patent Granted
17th Apr 20151:53 pmRNSHardman & Co issues research report
14th Apr 20157:00 amRNSUK Investor Show attendance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.